Blood-derived drugs: viral safety

Moutaouakkil, Youssef; Eldjaoudi, Rachid; Makram, Sanaa; Lamsaouri, Jamal; Bennana, Ahmed; Bousliman, Yassir

Batna Journal of Medical Sciences
Volume 3, Numéro 1, Pages 45-49
2016-06-29

Blood-derived Drugs: Viral Safety

Authors : Moutaouakkil Youssef . Eldjaoudi Rachid . Makram Sanaa . Lamsaouri Jamal . Bennana Ahmed . Bousliman Yassir .

Abstract

The stable blood products, called since 1995 “the medicines derived from blood”, are classified into five categories (albumin, clotting factors, protease inhibitors, immunoglobulins, biological glues). Their manufacture, dispensing, and pharmacovigilance (Correspondents) are provided primarily by the pharmacist. They have great importance in the compensation of constitutional or acquired deficiency of plasma proteins. Obtaining them from blood donation (voluntary, anonymous, and free), requires the application of several successive fractionation, merging, purification, elimination, and/or viral inactivation. The main techniques used in fractionation are, precipitation (by cold or ethanol) and chromatography, which also contributes to the reduction of a possible viral load. Viral securitisation is a decisive criterion for the evaluation of the drug under the authorization of placing it on the market. Other recombinant products have been developed; they have the advantage of being equally effective but safer than plasma products. We propose in our work to review key points on securing the viral transmission of medicines derived from blood.